Skip to main content
Top

Clinical & Experimental Metastasis

Issue 5/2017

Content (8 Articles)

Open Access Review Article

The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review

Ondřej Kubeček, Jan Laco, Jiří Špaček, Jiří Petera, Jindřich Kopecký, Alena Kubečková, Stanislav Filip

Research Paper

Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)

Martin Graversen, Sönke Detlefsen, Jon Kroll Bjerregaard, Per Pfeiffer, Michael Bau Mortensen

Research Paper

Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer

Garrett L. Jensen, Chad Tang, Kenneth R. Hess, Zhongxing Liao, Daniel R. Gomez

Research Paper

Portal branch ligation does not counteract the inhibiting effect of temsirolimus on extrahepatic colorectal metastatic growth

Sebastian Senger, Jens Sperling, Barbara Oberkircher, Martin K. Schilling, Otto Kollmar, Michael D. Menger, Christian Ziemann

Research Paper

Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases

M. Bartova, J. Hlavaty, Y. Tan, C. Singer, K. Pohlodek, J. Luha, I. Walter

Research Paper

Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?

Andrei Rios-Cantu, Ying Lu, Victor Melendez-Elizondo, Michael Chen, Alejandra Gutierrez-Range, Niloofar Fadaki, Suresh Thummala, Carla West-Coffee, James Cleaver, Mohammed Kashani–Sabet, Stanley P. L. Leong

Research Paper

Next generation sequencing of progressive colorectal liver metastases after portal vein embolization

Eve Simoneau, Jarred Chicoine, Sarita Negi, Ayat Salman, Anthoula Lazaris, Mazen Hassanain, Nicole Beauchemin, Stephanie Petrillo, David Valenti, Ramila Amre, Peter Metrakos

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine